Circulating immune complexes in patients with bone tumours
β Scribed by Amada Segal Eiras; R. A. Robins; R. W. Baldwin; V. S. Byers
- Publisher
- John Wiley and Sons
- Year
- 1980
- Tongue
- French
- Weight
- 456 KB
- Volume
- 25
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
Sera from 62 patients with osteogenic sarcoma and 12 with malignant giantβcell tumour were tested for the presence of immune complexes by the ^125^IβClq binding assay. Elevated serum Clq binding activity was found in 67.7% of the osteogenic sarcoma patients and in 75% of the giantβcell tumour patients. These results were compared with those obtained with five sera from patients with benign bone tumours and 20 sera from normal young donors. In the last two groups, the incidence of elevated Clqβbinding activity was 0% and 5%, respectively. In some patients with giantβcell tumours, preand postβoperative serum samples were studied, showing a decrease in test values after tumour resection. Preliminary sequential studies of individual patients indicate that the ^125^IβClq binding assay may be useful for monitoring patients with bone tumours.
π SIMILAR VOLUMES
An assay which could prospectively predict a response to chemotherapy prior to instituting therapy would be beneficial, especially for nonresponders. We evaluated at random a total of 50 patients with previously untreated stage 111 and IV head and neck squamous cell carcinoma for T-cell subsets and